ProfileGDS5678 / 1456348_x_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 43% 42% 42% 41% 41% 43% 41% 41% 55% 43% 42% 41% 42% 42% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.0306343
GSM967853U87-EV human glioblastoma xenograft - Control 22.9717242
GSM967854U87-EV human glioblastoma xenograft - Control 32.9758942
GSM967855U87-EV human glioblastoma xenograft - Control 42.8872841
GSM967856U87-EV human glioblastoma xenograft - Control 52.9004541
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.0778143
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.0197841
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.9384641
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.3633155
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.9921343
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.96542
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.9222641
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.9842642
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.9610542